Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antioxidants and cataracts

This article was originally published in The Tan Sheet

Executive Summary

Roche European American Cataract Trial (REACT) finds three-year daily use of antioxidant cocktail produces "small deceleration in progression of [age-related cataract]," Leo Chylack, MD, Brigham & Women's Hospital, Boston, et al., report in November Ophthalmic Epidemiology. Partly funded by Hoffmann-La Roche and Roche Vitamins, trial included 297 American and British early ARC patients randomly dosed with placebo or combinations of 18 mg beta carotene, 750 mg vitamin C, 600 mg vitamin E. Cataract severity was documented using serial digital retroillumination imagery, progression was measured as "increase % pixels opaque." Findings follow recent research showing antioxidants and zinc reduce risk of developing advanced age-related macular degeneration (1"The Tan Sheet" Oct. 15, p. 3)...

You may also be interested in...



Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel